See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):Large accelerated filer¨Accelerated filer¨Non-accelerated filerýSmaller reporting company¨(Do not check if a smaller reporting company)Emerging growth companyýIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.ýCALCULATION OF REGISTRATION FEETitle of each class  of securitiesto be registeredAmount to beregistered(1)Proposedmaximumoffering price pershare(2)Proposedmaximumaggregate offeringprice(2)Amount ofregistrationfeeCommon Stock, $0.001 par value per share5,175,000$22.74$117,679,500$14,652(1)Includes additional shares that the underwriters have an option to purchase.(2)Estimated solely for purposes of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, on the basis of the average high and low sales price of the Registrant’s common stock as reported by the Nasdaq Global Select Market on May 31, 2018.The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section 8(a), may determine.The information in this preliminary prospectus is not complete and may be changed.
In addition, the selling stockholders are selling shares of common stock in this offering and we will not receive any of the proceeds from the sale of shares to be offered by the selling stockholders.We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to support the commercialization of XHANCE, to fund further development efforts for XHANCE, including the initiation of a clinical program necessary to seek approval for a follow-on indication of XHANCE for the treatment of chronic sinusitis, and for other working capital and general corporate purposes, including debt service costs.See “Use of Proceeds” on page16of this prospectus for a more complete description.Risk factorsYou should read the “Risk Factors” section beginning on page9of this prospectus and in the documents incorporated by reference herein for a discussion of certain of the factors to consider carefully before deciding to purchase any shares of our common stock.Nasdaq Global SelectMarket Symbol“OPTN”Unless otherwise indicated, the number of shares of our common stock to be outstanding after this offering is based on 37,909,058 shares of common stock outstanding as of March 31, 2018, and excludes:§6,309,453shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2018 at a weighted‑average exercise price of$9.74per share;§37,800shares of common stock issuable upon the exercise of stock options granted since March 31, 2018 at a weighted‑average exercise price of$21.51per share;§1,890,489 shares of common stock issuable upon the exercise of warrants to purchase common stock outstanding as of March 31, 2018 at an exercise price of $8.16 per share;§304,401 shares of common stock issued upon the exercise of stock options subsequent to March 31, 2018 at a weighted average exercise price of $2.25 per share;5§7,098 shares of common stock issued upon the exercise of warrants subsequent to March 31, 2018 at an exercise price of $8.16 per share;§1,884,403shares of common stock reserved for future issuance under our Amended and Restated 2010 Stock Incentive Plan, or the 2010 Plan, as of March 31, 2018, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2010 Plan; and§522,420shares of common stock reserved for future issuance under our 2017 Employee Stock Purchase Plan, or the 2017 ESPP, as of March 31, 2018, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2017 ESPP.Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding options and warrants described above and no exercise by the underwriters of their option to purchase up to an additional675,000shares of our common stock from us and the selling stockholders in this offering.6SUMMARY CONSOLIDATED FINANCIAL DATAThe following tables set forth, for the periods and as of the date indicated, our summary consolidated financial data.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions described under the section titled “Risk Factors” in this prospectus and in our 2017 Annual Report and 2018 Quarterly Report, which are incorporated by reference in this prospectus, and elsewhere in this prospectus and in the documents incorporated by reference in this prospectus, regarding, among other things:▪the potential advantages of XHANCE and our product candidates;▪the potential benefits of our Xperience Program and its potential effect on future financial results;▪our goal for 75% of commercially insured lives to have access to XHANCE in a Tier 3 formulary position with a low “hassle factor” by the end of 2018;▪our commercial initiatives and objectives related to XHANCE and our product candidates;▪our planned product development activities, studies and clinical trials, including our plans to initiate a clinical program of XHANCE in the fourth quarter of 2018 in pursuit of a supplemental indication for chronic sinusitis;▪our expectation that our existing cash and cash equivalents and the net proceeds to us from this offering will provide sufficient capital to us to allow us to continue to service our debt and become profitable;▪our expectation that our operating expenses in 2018 will be in the range of $119.0 - $125.0 million;▪the rate and degree of market acceptance of XHANCE and our product candidates;▪the size and growth potential of the markets for XHANCE and our product candidates, and our ability to service those markets;▪our ability to maintain regulatory approval of XHANCE and our product candidates;▪our ability to attract collaborators with development, regulatory and commercialization expertise;▪regulatory developments in the United States and foreign countries;▪our ability to operate our business without infringing the intellectual property rights of others;▪the scope and duration of patent protection and other barriers to entry that we expect to benefit XHANCE and our product candidates;▪the performance of our third-party suppliers, manufacturers and contract sales organizations;▪the success of competing products that are or become available;13▪our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for XHANCE and our other product candidates and to avoid claims of infringement;▪our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act;▪our use of proceeds from this offering; and▪the accuracy of our estimates regarding expenses, future revenue, capital requirements and need for additional financing.Moreover, we operate in a very competitive and rapidly changing environment.
The selected consolidated financial data should be read together with our financial statements and related notes, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” incorporated herein by reference.23Years ended December 31,Three Months ended March 31,(in thousands, except share and per share data)20152016201720172018Consolidated Statement of Operations Data:Net product revenues$—$—$—$—$865Licensing revenues8547,500———Total revenues8547,500——865Cost of product sales————200Gross margin8547,500——665Operating expenses:Research and development22,15615,31116,8324,2301,701Selling, general and administrative6,0066,86931,6983,07328,011Total operating expenses28,16222,18048,5307,30329,712(Loss) income from operations(28,077)25,320(48,530)(7,303)(29,047)Other expense, net:2372,7073727721,525Net (loss) income(28,314)22,613(48,902)(8,075)(30,572)Deemed dividend(9,992)(11,005)(11,969)(3,067)—Accretion of redeemable convertible preferred stock(2,069)(2,109)(1,096)(528)—Net (loss) income attributable to common stockholders$(40,375)$9,499$(61,967)$(11,670)$(30,572)Net (loss) income per share of common stock,basic$(9.97)$0.40$(5.63)$(2.87)$(0.81)diluted$(9.97)$0.32$(5.63)$(2.87)$(0.81)Weighted average common shares outstanding,basic4,049,6684,054,31610,999,1214,067,71737,849,199diluted4,049,6684,980,18110,999,1214,067,71737,849,19924As of December 31,As of March 31, 2018(in thousands)201520162017Consolidated Balance Sheet Data:Cash and cash equivalents$15,198$36,797$234,854$209,771Working capital(1)8,62434,765223,390194,581Total assets16,00941,551241,136220,562Long-term debt, net——71,86371,963Convertible notes14,48015,256——Redeemable convertible preferred stock155,059168,173——Additional paid-in capital——365,838368,018Accumulated deficit(161,255)(151,102)(211,269)(241,841)Total stockholders' equity (deficit)(161,392)(151,197)154,496126,111(1)Working capital is calculated as current assets minus current liabilities.25CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONSThe following includes a summary of transactions since January 1, 2015 to which we have been a party in which the amount involved exceeded or will exceed $120,000, and in which any of our directors, director nominees, executive officers or beneficial owners of more than 5% of our capital stock, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements that are described in the “Executive Compensation”and“Director Compensation”sections of our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 25, 2018, which is incorporated by reference in this prospectus.Convertible Preferred Stock FinancingsIn July 2014, we issued an aggregate of 1,419,781 shares of our Series C-1 Preferred Stock at a purchase price of $21.13 per share, for aggregate consideration of $30.0 million.